Polypharmacy, defined as being prescribed 5 or more medications, has been shown to be associated with a decline in mental and physical functioning in elderly patients. Despite this, elderly patients are currently being prescribed a median of 7 medications, which often causes more harm than benefit, and emphasizes the importance of deprescribing.
Methods
Five classes of potentially inappropriate medications for the elderly population, especially for the aging brain, are discussed, including anticholinergics, benzodiazepines, antipsychotics, opioids, and proton pump inhibitors. Recommendations regarding these medications were collected from the 2015 Beer's Criteria, the Screening Tool of Older Person's Prescriptions (STOPP) criteria, the Screening Tool to Alert doctors to the Right Treatment (START) criteria, and the Fit fOR The Aged (FORTA) list. The PubMed database was also searched for the most recent evidence regarding prescription patterns, adverse effects, and recommendations regarding discontinuation of these medications in older adults.
Results
Anticholinergics, benzodiazepines, antipsychotics, and opioids were all found to have significant adverse effects in the elderly population. All of the discussed medication classes have been shown to be successfully deprescribable.
Conclusions
Polypharmacy increases the risk of adverse drug reactions and hospitalizations in geriatric patients. Rational deprescribing of anti-cholinergics, benzodiazepines, antipsychotics, opioids, and proton pump inhibitors in selected patients may be a good first step to reducing this risk.
Get full access to this article
View all access options for this article.
References
1.
FaunceTA. Global health & global aging. JAMA.2008; 299: 2333–2334.
2.
StuckAEBeersMHSteinerA. Inappropriate medication use in community-residing older persons. Arch Intern Med.1994; 154: 2195–2200.
3.
HyttinenVJyrkkäJSaastamoinenLK. Patient-and health care-related factors associated with initiation of potentially inappropriate medication in community-dwelling older persons. Basic Clin Pharmacol Toxicol.2019; 124: 74–83.
4.
KlotzU.Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev.2009; 41: 67–76.
5.
HazraNCDreganAJacksonS. Drug utilization and inappropriate prescribing in centenarians. J Am Geriatr Soc.2016; 64: 1079–1084.
6.
JyrkkäJ, EnlundH, LavikainenP, . Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three‐year period in an elderly population. Pharmacoepidemiol Drug Saf.2011; 20: 514–522.
7.
ScottIALe CouteurDG. Physicians need to take the lead in deprescribing. Internal Med J.2015; 45: 352–356.
8.
ReeveEGnjidicDLongJ. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol.2015; 80: 1254–1268.
9.
MasnoonNShakibSKalisch-EllettL. What is polypharmacy? A systematic review of definitions. BMC Geriatrics.2017; 17: 230.
10.
PalagyiAKeayLHarperJ. Barricades and brickwalls - a qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC Geriatrics.2016; 16: 15.
11.
RochonPAGurwitzJH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ.1997; 315: 1096–1099.
12.
MaginPGoodeSPondD.G Ps medications and older people: a qualitative study of general practitioners’ approaches to potentially inappropriate medications in older people. Australas J Ageing.2015; 34: 134–139.
13.
GarfinkelDManginD.Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Int Med.2010; 170: 1648–1654.
14.
McGrathKHajjarERKumarC. Deprescribing: a simple method for reducing polypharmacy. J Fam Pract.2017; 66: 436–445.
15.
SchulingJGebbenHVeehofLJ. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract.2012; 13: 56.
16.
MoLDingDPuSY. Patients aged 80 years or older are encountered more potentially inappropriate medication use. Chin Med J (Engl).2016; 129: 22–27.
17.
AnthierensSTansensAPetrovicM. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract.2010; 11: 65.
18.
The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc.2015; 63: 2227–2246.
19.
O'MahonyD, O'SullivanD, ByrneS, . Stopp/Start criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing.2015; 44: 213–218.
20.
PazanFWeissCWehlingM.The FORTA (Fit fOR The Aged) List 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging.2016; 33: 447–449.
21.
Remom-GuiterasAMeyerGThurmannPA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol.2015; 71: 861–875.
22.
HoltSSchmiedlSThurmannPA. Potentially inappropriate medications in the elderly: the Priscus list. Dtsch Ärztebl Int.2010; 107: 543–551.
23.
SteinmanMABeizerJLDuBeauCE. How to use the American Geriatrics Society 2015 Beers Criteria -a guide for patients, clinicians, health systems, and payers. J Am Geriatr Soc.2015; 63: e1–e7.
24.
By the 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc.2019; 67: 674–694.
25.
GerretsenPPollockBG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011; 10: 751–765.
26.
NishtalaPSSalahudeenMSHilmerSN. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf.2016; 15: 753–768.
27.
RisacherSLMcDonaldBCTallmanEF. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol.2016; 73: 721–732.
28.
CampbellNBoustaniMLimbilT. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging.2009; 4: 225–233.
29.
GraySLAndersonMLDublinS. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med.2015; 175: 401–407.
30.
SalahudeenMSDuffullSBNishtalaPS. Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review. Drugs Aging.2014; 31: 185–192.
31.
LindseyPL. Psychotropic medication use among older adults: what all nurses need to know. J Gerontol Nurs.2009; 35: 28–38.
32.
Billioti de GageS, MorideY, DucruetT, . Benzodiazepine use and risk of Alzheimer's disease: a case-control study. BMJ.2014; 349: g5205. doi: https://doi.org/10.1136/bmj.g5205.
33.
FuloneILopesLC. Potentially inappropriate prescriptions for elderly people taking antidepressant: comparative tools. BMC Geriatrics.2017; 17: 278.
34.
Diaz-GutiérrezMJ, Martínez-CengotitabengoaM, Sáez de AdanaE, . Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas.2017; 101: 17–22.
35.
Van der HooftCS, SchoofsMW, ZiereG, . Inappropriate benzodiazepine use in older adults and the risk of fracture. Br J Clin Pharmacol.2008; 66: 276–282.
36.
WangPSBohnRLGlynnRJ. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry.2001; 158: 892–898.
37.
MarkotaMRummansTABostwickJMLapidMI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc.2016; 91: 1632–1639.
38.
GraySLDublinSYuO. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ.2016; 352: i90.
39.
IslamMMIqbalUWaltherB. Benzodiazepine use and risk of dementia in the elderly population: a systemic review and meta-analysis. Neuroepidemiology. 2016; 47: 181–191.
40.
ImfeldPBodmerMJickSS. Benzodiazepine use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis. Drug Saf.2015; 38: 909–919.
41.
TannenbaumCMartinPTamblynR. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014; 174: 890–898.
42.
IyerSNaganathanVMcLachlanAJ. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging.2008; 25: 1021–1031.
43.
BloomHGAhmedIAlessiCA. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc.2009; 57: 761–789.
44.
StanleyMAWilsonNLNovyDM. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA.2009; 301: 1460–1467.
45.
U.S. Food and Drug Administration Center for Drug Evaluation and Research. FDA Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http://psychrights.org/drugs/FDAantipsychotics4elderlywarning.htm. Published April 11, 2005. Accessed May 30, 2018.
MiaronsMCabibCBarónFJ. Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms. Eur J Clin Pharmacol.2017; 73: 1389–1398.
48.
HsuW TEsmaily-FardALaiCC. Antipsychotics and the risk of cerebrovascular accident: a systematic review and meta-analysis of observational studies. J Am Med Dir Assoc.2017; 8: 692–699.
49.
RaoASulimanAStoryG. Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia. Int J Methods Psychiatr Res.2016; 5: 289–298.
50.
Schneider-ThomaJEfthimiouOHuhnM. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomized controlled trials. Lancet Psychiatry.2018; 5: 653–663.
51.
BallardCLanaMMTheodoulouM. A randomized, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLOS Medicine.2008; 5: e76.
52.
BallardCHanneyMLTheodoulouM. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo controlled trial. Lancet Neurol.2009; 8: 151–157.
53.
DevanandDMintzerJSchultzSK. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med.2012; 367: 1497–1507.
54.
De OliveiraAM, RadanovicM, de MelloPCH, . Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. Biomed Res Int.2015; 2015: 218980.
55.
DublinSWalkerRLGraySL. Prescription opioids and risk of dementia or cognitive decline: a prospective cohort study. J am Geriatr Soc.2015; 63: 1519–1526.
56.
PapaleonitouMHendersonCRJr, TurnerBJ, . Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J am Geriatr Soc.2010; 58: 1353–1369.
57.
CarewAMComiskeyC.Treatment for opioid use and outcomes in older adults: a systematic literature review. Drug Alcohol Depend.2018; 182: 48–57.
58.
GuerardEJClearyJF. Managing cancer pain in older adults. Cancer J.2017; 23: 242–245.
59.
MegaleRZDevezaLABlythFM. Efficacy and safety of oral and transdermal opioid analgesics for musculoskeletal pain in older adults: a systematic review of randomized, placebo-controlled trials. J Pain.2018; 19: 475.e1-475.e24. doi: 10.1016/j.jpain.2017.12.001.
60.
SwartLMvan der ZandenV, SpiesPE, . The comparative risk of delirium with different opioids: a systematic review. Drugs Aging.2017; 35: 437–443.
61.
RamageSNAnthonyICCarnieFW. Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. Neuropathol Appl Neurobiol.2005; 31: 439–448.
62.
AnthonyICNorrbyKEDingwallT. Predisposition to accelerated Alzheimer‐related changes in the brains of human immunodeficiency virus negative opiate abusers. Brain.2010; 133: 3685–3698.
63.
GraySLWalkerRLDublinS. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geri Soc.2017; 66: 247–253.
64.
GommW von Holt K, Thome F, . Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol.2016; 73: 410–416.
65.
TaiSYChienCYWuDC. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS ONE.2017; 12: e0171006.
66.
NardinoRJVenderRJHerbertPN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol.2000; 95: 3118–3122.
67.
HeidelbaughJJGoldbergKLInadomiJM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care.2010; 16: e228–e234.
68.
ThompsonWHogelMLiY. Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care. J Am Med Dir Assoc.2016; 17: 673.e1-e4.
69.
LeeCLoAUbhiK. Outcome after discontinuation of proton pump inhibitors at a residential care site: quality improvement project. Can J Hosp Pharm.2017; 70: 215–223.
70.
BembenNM. Deprescribing: an application to medication management in older adults. Pharmacotherapy. 2016; 36: 774–780.
